Medical Marijuana Effects in Movement Disorders, Focus on Huntington Disease; A Literature Review

Edward Akinyemi¹, Gavin Randhawa¹, Victor Longoria¹ and Rana Zeine¹, ²

¹Saint James School of Medicine, Basic Medical Sciences, 1480 Renaissance Drive, Park Ridge, IL 60068 USA; ²KEAN University, School of Natural Sciences, Biology Department, 1000 Morris Ave., Union, NJ 07083 USA

ABSTRACT - Purpose: We aimed to comprehensively evaluate the effects of medical marijuana on symptoms that are relevant to movement disorders with a focus on Huntington disease (HD). Methods: A systematic review by literature search through PubMed and EBSCO electronic databases was conducted for relevant studies reported after 2002 on the effects of medical marijuana or cannabis use on tremor, spasm, spasticity, chorea, sleep quality and HD-specific rating scales. Study selection, quality assessment and data extraction was performed by three reviewers. Outcome measures were changes in psychomotor, and sleep related symptoms. The methodological quality of the included studies was evaluated. Results: A total of 22 studies were reviewed. There was strong evidence for significant improvement in the neurologic symptoms of spasms, tremors, spasticity, chorea, and quality of sleep following treatment with medical marijuana. Analysis of specific motor symptoms revealed significant improvement after treatment in tremors and rigidity. Furthermore, all pretreatment and post-treatment measures indicated a significant increase in average number of hours slept. Conclusion: Larger scale studies are warranted to test the benefits of medical marijuana in HD patients. In the meanwhile, clinicians may consider prescribing medical marijuana as part of their strategy for better symptomatic treatment of patients with HD.

INTRODUCTION

Neurodegenerative diseases are characterized by a loss of neurons and neuropathological lesions distributed in particular regions of the central nervous system. Huntington disease (HD) is an autosomal dominant inherited neurodegenerative disease caused by an elongated CAG repeat (36 repeats or more) in the huntingtin gene on the short arm of chromosome 4p16.3 (1,2). In HD, there is neuronal loss in the neostriatum, most markedly in the caudate nucleus, and progressing through the putamen (1). Clinically, HD is characterized by worsening involuntary choreic movements, behavioral and psychiatric disturbances, and dementia (2). Psychomotor processes become severely retarded as patients experience psychiatric symptoms and cognitive decline (2). The prevalence of HD in the Caucasian population is estimated at 1/10,000-1/20,000 with mean age of onset at 30-50 years (2). Cannabidiol (CBD) is regarded as a compound with therapeutic potential against neurodegenerative and hyperkinetic disorders in view of its neuroprotective effects (3). The endocannabinoid system has been implicated in a broad range of physiological functions such as cognition, mood, motor control, feeding behaviors, and pain (4). The clinical manifestation of movement disorders includes motor symptoms such as resting tremors, rigidity (cogwheel…), akinesia, bradykinesia, loss of righting reflex, chorea, gait disturbances (shuffling gait…), spasticity, and loss of automatic movement, retrocollis, impaired eye movement (downward gaze), pseudobulbar palsy; as well as autonomic dysfunction, cognitive impairment, and depression (1). Preclinical research suggests that cannabinoids...
have symptomatic and neuroprotective potential for a variety of neurologic conditions including movement disorders (3, 4). Marijuana contains around 60 pharmacologically active compounds known as “cannabinoids” (5).

Studies have shown that non-psychoactive cannabidiol is well tolerated and safe in humans even at high doses (6). Cannabis strains high in CBD content have been used for treatment of patients with intractable seizures, and to relieve symptoms in patients with chronic pain, arthritis, tremors, dementia, post-traumatic stress disorder, and in patients undergoing chemotherapy (6, 7). The medical properties of CBD that have been demonstrated in animal studies include antiemetic, anticonvulsant, antipsychotic, anti-inflammatory, antioxidant, anti-cancer, anxiolytic, and anti-depressant effects (7). As of July 2019, 33 states and the District of Columbia in the United States of America have enacted laws allowing marijuana use to treat certain medical conditions (8).

The most common cause of death in HD is pneumonia, followed by suicide (2). In this study, we focus on the effects of medical marijuana on the symptoms of HD including emotional turmoil (depression, apathy, irritability, anxiety, obsessive behavior), cognitive loss (inability to focus, plan, recall or make decisions; impaired insight), and physical deterioration (weight loss, involuntary movements, diminished coordination, difficulty walking, talking, and swallowing) (9).

METHODS

A systematic review was conducted by literature search through PubMed and EBSCO electronic databases. The text words “marijuana”, “cannabis”, “THC”, “medical marijuana”, “CBD”, “cannabidiol”, “Nabilone”, “Sativex®”, with the use of the Boolean operator “AND” the terms “Huntington disease”, “chorea”, “rigidity”, “psychomotor decline”, “cognitive impairment”, “tremor” “gait disturbance”, “akinesia”, “bradykinesia”, “retrocollis” and “depression” were used to identify relevant studies discussing the effectiveness of medical marijuana in patients with HD.

The inclusion criteria were the following: 1) must be a scholarly or peer-reviewed source, 2) a relevant article published after 2002, and 3) articles published in the English language only. Exclusion criteria were the following: 1) publications potentially used for marketing purposes, 2) articles in foreign languages, 3) articles dated prior to 2002.

Outcome measures included any changes in symptoms such as choreic movements, chorea, rigidity, tremors, psychomotor decline, cognitive impairment, and depression. The quality of evidence was assessed by scoring the articles according to the following rating scheme: (1) properly conducted randomized clinical trial, (2) well-designed controlled trial without randomization or prospective comparative cohort study, (3) case-control study or retrospective cohort study, (4) cross-sectional study or case series, (5) case reports or opinion of respected authorities.

RESULTS

All together 50 relevant reports were identified, 43 through direct and 7 by indirect searches. After cutting the redundancies, 27 full-text articles were assessed, from which 22 were found eligible for inclusion.

The outcomes data were extracted from studies conducted on populations with several conditions including multiple sclerosis (MS), parkinson disease (PD), fibromyalgia, posttraumatic stress disorder (PTSD) and HD. Effects of cannabis use or medical marijuana treatments were tabulated by signs and symptoms of relevance to HD including spasm and spasticity (Table 1), tremor (Table 2), sleep quality (Tables 1 and 3), chorea, motor and dystonia subscales on the Unified Huntington’s Disease Rating Scale (UHDRS) which assesses motor function, cognitive function, behavioral abnormalities, and functional capacity (Table 4), and biochemical markers in animal models (Tables 5 and 6).
Table 1: Effects of medical marijuana on spasticity

| Study                          | Year | Findings                                                                 | Formulations                                                                 |
|--------------------------------|------|--------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Zajicek et al. *Randomized Controlled Trial* (10) | 2003 | 630 MS patients were enrolled in a randomized, placebo-controlled clinical trial at 33 centers in the UK. There was evidence of a treatment effect on patient-reported spasticity and pain (p=0.003), with improvement in spasticity reported in 61% (n=121, 95% CI 54.6-68.2), 60% (n=108, 52.5-66.8), and 46% (n=91, 39.0-52.9) of participants on cannabis extract, Δ9-THC, and placebo, respectively (10). | Oral cannabis extract capsules containing 2.5 mg Δ9-THC equivalent and 1.25 mg CBD and < 5% other cannabinoid vs Δ9-THC alone |
| Vaney et al. *Randomized Controlled Trial* (11) | 2004 | 57 MS patients were enrolled in a prospective randomized, double-blind, placebo-controlled, crossover study in Switzerland. Treatment consisted of cannabis-extract capsules standardized to 2.5 mg tetrahydrocannabinol (THC) and 0.9 mg cannabinol (CBD). In 37 patients who received 90% of their prescribed dose (THC and CBD), significant improvements in spasm frequency were observed (p=0.013) (11). | Cannabis-extract capsules standardized to 2.5 mg THC and 0.9 mg CBD |
| Brady et al. *Open-label pilot study* (12) | 2004 | 21 MS patients were recruited for treatment with cannabis-based extracts and data from 15 were evaluated in the UK. Urinary urgency, incontinence, and nocturia decreased significantly (p <0.05) and patient self-assessment of pain, spasticity and quality of sleep improved significantly (p <0.05) (12). | Δ9-THC and CBD 2.5 mg of each per spray for eight weeks followed by 2.5 mg THC-only per spray for a further eight weeks |
| Novotna et al. *Randomized Controlled Trial* (13) | 2011 | 572 MS patients were enrolled in a randomized, double-blind, placebo-controlled, parallel-group, enriched-design study. Results showed significant improvements in spasticity Numeric Rating Scale (NRS), Spasm Frequency Score and Sleep Disturbance following treatment with nabiximols (Sativex®) (p<0.001) (13). | Nabiximols (Sativex®) study medication was delivered using a pump action oromucosal spray. Each 100-μl actuation of active medication delivered 2.7 mg THC and 2.5 mg CBD to the oral mucosa. Subjects were restricted to a maximum of 12 sprays in any 24-h period. |

Table 2: Effects of medical marijuana on tremor

| Study                          | Year | Findings                                                                 | Formulations                                                                 |
|--------------------------------|------|--------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Venderova et al. *Cross-sectional study* (14) | 2004 | Of 339 PD patients surveyed, 25% reported Cannabis use and, of those, 31% reported improvement of resting tremor. Patients using cannabis for at least 3 months reported significant improvement in resting tremors (p<0.01) (14). | Determined patients’ personal use of cannabis by survey questions and correlated change in symptoms with concentrations of 11-nor-δ-9-THCOOH in urine |
| Lotan et al. *Case-control study* (15) | 2014 | 22 PD patients attending the motor disorder clinic of a tertiary medical center in Israel, who were evaluated on the motor Unified Parkinson Disease Rating Scale at baseline and 30 minutes after smoking cannabis, were found to have significant improvement in tremor (p<0.001), bradykinesia (p<0.001) and rigidity (p=0.004) (15). | Smoking cannabis 0.5 grams |
Table 3: Effects of cannabis use on sleep quality

| Study                        | Year | Findings                                                                                                                                                                                                                                                                                                                                 | Formulations                                                                                                                                                                                                 |
|------------------------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Fiz et al. Cross-sectional   | 2011 | 28 fibromyalgia patients surveyed in Spain reported no significant changes in overall sleep quality between cannabis-users and non-users on the Pittsburgh Sleep Quality Index (PSQI) (16).                                                                                           | Determined patients’ personal use of cannabis by survey questions probing patterns of smoking and eating recreational cannabis (hashish or marijuana)                                                                 |
| Tringale and Jensen Cohort Study | 2011 | Amongst 166 subjects analyzed in a focused, retrospective cohort study from two cannabis clinics in Southern California (Ventura and San Clemente), there was a significant decrease in total time to fall asleep after the use of cannabis (p=0.001) (17).                                      | Oral, pipe, bong, vaporizer, and joints route of administration of cannabis. Use per week up to 20 grams.                                                                                                                                                          |
| Cameron et al. Cohort study  | 2014 | 101 subjects from a correctional population with PTSD in Ontario, Canada reported a significant increase in mean number of hours slept from 5.0 [SD 1.4] pretreatment, to 7.2 [SD 1.2] posttreatment (p<0.001) (18).                                                                 | Synthetic Nabilone 4.0 mg given in powder form with water                                                                                                                                                    |

Table 4: Effects of medical marijuana in Huntington disease patients

| Study                        | Year | Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Formulations                                                                                                                                                                                                 |
|------------------------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Curtis and Rickards Case report | 2006 | A 43-year-old female HD patient in the UK reported improvements in behavior and reduction of chorea maintained by daily dosage of Nabilone (19).                                                                                                                                                                                                                                                                                                                                                                  | Nabilone, Synthetic 9-keto cannabinoid, 1 mg capsule per day                                                                                                                                                                                                                   |
| Curtis et al. Randomized Controlled Trial | 2009 | 44 HD patients were enrolled in a double-blind, placebo-controlled, cross-over study of nabilone (1 or 2 mg) versus placebo in the UK. Results demonstrated significant improvement in chorea (p=0.009) and neuropsychiatric index (p=0.04); and a trend for improvement in behavior score (p=0.06) (20).                                                                 | Nabilone 1 or 2 mg capsule                                                                                                                                                                                                                                                     |
| Saft et al. Case-control study | 2018 | 7 HD patients in Europe were evaluated before and after the start of cannabinoids without any other changes in medication. Their Unified Huntington’s Disease Rating Scale (UHDRS) motor score improved from 70.9 [SD 25.5] to 60.6 [SD 26.9] (p=0.018), and the dystonia subscore improved from 12.3 [SD 4.0] to 8.9 [3.6] (p=0.0180) (21).                                                                 | Sativex® 12 sprays or Dronabinol 4-4-5 drops (9.1 mg) or Sativex ® 7 sprays or Dronabinol 2-2-1 drops (3.6 mg) or Dronabinol 2-0-2 drops (2.8 mg) or Nabilone 0.5 mg-0-1 mg or Dronabinol 1-1-1 drops (2.2 mg) or Dronabinol 1-1-0 drops (0.5 mg)                        |
| López-Sendón Moreno et al. Randomized Controlled Trial | 2016 | 26 patients were enrolled in a double-blind, randomized, placebo-controlled, cross-over pilot clinical trial with Sativex® in Spain. 24 completed the trial which showed no differences on the motor subscore of the Unified Huntington’s Disease Rating Scale (p = 0.286) (22).                                                                 | Both Sativex® and placebo were dispensed as an oral spray, to be administered up to 12 sprays/day for 12 weeks.                                                                                                               |
Table 5: Loss of striatal type 1 cannabinoid receptors in Huntington-like animal model

| Study                               | Year | Findings                                                                                                                                                                                                 | Formulations                                                                 |
|-------------------------------------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Blazquez et al Experimental Study    | 2010 | Pharmacological activation of CB1 cannabinoid receptors ameliorates Huntington’s disease-like symptomatology, neuropathology and molecular pathology in R6/2 (Huntington-like) mice (23). Expression of the endocannabinoid-deactivating enzyme fatty acid amide hydrolase (FAAH) is higher in symptomatic (8- to 12-week-old) R6/2 mice than in their wild-type littermates (23). | THC 2 mg/kg body weight per day intraperitoneally                             |

Table 6: Results reporting the recovery of N-acetyl-aspartate/Choline (NAA/Cho) in mice: Reduced NAA/Cho levels possibly reflect neuronal and mitochondrial dysfunction/damage

| Study                               | Year | Findings                                                                                                                                                                                                 | Formulations                                                                 |
|-------------------------------------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Valdeolivas et al Experimental Study| 2017 | R6/2 and wild-type mice were housed in rooms with controlled photoperiod with free access to standard food and water. Sativex®-like combination of phytocannabinoids treatment completely reversed the reduction in NAA/Cho (p<0.005) (24). | Δ9-THC- and CBD-enriched botanical extracts combined in a Sativex®-like ratio 1:1 (4.5 mg/kg equivalent to 3 mg/kg of pure CBD + Δ9-THC) |

Studies have demonstrated that Fatty acid amide hydrolase (FAAH), an anandamide-degrading enzyme that deactivates endocannabinoids, is upregulated in striatal brain tissue from symptomatic Huntington disease-like R6/2 mice, as well as in Huntington disease patients (23).

NAA/Cho (N-acetyl-aspartate/Choline) levels were shown to be reduced in Huntington disease-like mice, possibly reflecting neuronal and mitochondrial dysfunction/damage (24). Treatment with either a broad-spectrum cannabinoid, or combinations of cannabinoids with complementary profiles, have been found to delay progression in an experimental Huntington disease model, and to preserve the integrity of striatal neurons demonstrating that a Sativex®-like combination of phytocannabinoids treatment completely reversed the reduction in NAA/Cho (p<0.005) (24).

**DISCUSSION**

A systematic review was conducted to evaluate the strength of evidence for the efficacy of medical marijuana in alleviating the symptoms that manifest in movement disorders that are particularly relevant in Huntington disease. The eligible studies included 5 randomized placebo-controlled clinical trials, 2 case-control studies, 2 cross-sectional studies, 2 cohort studies, 2 experimental observational studies, 1 open-label pilot study, and 1 case report. The studies of highest quality were the 5 randomized placebo/controlled trials which included a sum total of 1,329 human subjects. The human studies reviewed demonstrated therapeutic effects for medical marijuana in the management of movement disorder symptomatology including the use of Sativex®, which is an oral spray that contains a combination of tetrahydrocannabinol and cannabidiol, and Nabilone, which is a synthetic cannabinoid capsule that is a selective agonist for CB1 and CB2 receptors (4,25). It is assumed that the effects demonstrated by data extracted from the studies which utilized standardized pharmaceutical formulations would be more clinically reliable than those from survey studies which collected self-reported accounts of cannabis use. Furthermore, since pain is also prevalent in Huntington disease patients, the use of medical marijuana could be helpful for them in light of evidence that cannabinoid-based pharmacotherapies might be effective.
for management of chronic pain (26). It would be expected that any benefits experienced by patients would have been longer lasting after ingestion as compared to inhalation.

Although the majority of studies showed statistically significant results favoring the use of medical marijuana, especially for improving motor symptoms and quality of sleep, the number of Huntington disease patients who were available to participate in these studies was a sum total of 78, and it was necessary to examine the effects seen in patients diagnosed with other diseases in which the same type of symptoms exist. As such, the findings of decreased spasticity were demonstrated primarily by measurements in patients with the autoimmune demyelinating disease multiple sclerosis (Table 1). The findings of reduced tremor were demonstrated primarily by assessments in patients with the nigrostriatal neurodegenerative parkinson disease (Table 2). The findings of improved sleep quality were derived from populations of respondents with either the chronic pain disorder fibromyalgia, or the anxiety disorder PTSD, or miscellaneous conditions for which they sought treatment at a cannabis clinic (Table 3). The findings that were shown in patients with the basal ganglia neurodegenerative Huntington disease were improvements in chorea, improvements in the neuropsychiatric index, and trends for improvements in the Unified Huntington’s Disease Rating Scale motor score, the dystonia subscore and behavior score (Table 4).

The animal studies reviewed included experimental observations following activation of CB1 receptors by THC that demonstrate a protective role of the endocannabinoid system against the development and progression of symptoms in R6/2 murine models for Huntington-like disease (22,23).

CONCLUSION

The observed or reported improvements in the symptoms of movement disorders are consistent with the principal pharmacological effects of THC and CBD. Alleviation of spasticity, tremors, chorea and dystonia might be attributed to the muscle relaxant and analgesic effects of both THC and CBD. Improvements in sleep quality, behavioral and neuropsychiatric indices could be attributable to the anxiolytic, neuroprotective, anti-oxidant, anticonvulsant, and anti-psychotic activities of CBD. Large scale, randomized, clinical trials, perhaps international collaborative efforts, are warranted to test the use of medical marijuana more widely in HD patient populations, and who may be at various stages of disease progression. Acknowledging the need for determining that the therapeutic benefits shall outweigh any long term risks, we nevertheless recommend that physicians consider prescribing medical marijuana as adjunctive treatment for symptomatic relief to slow the progression or reverse spasms, tremor, spasticity, chorea, dystonia, behavioral, neuropsychiatric and sleep disturbances in patients with Huntington disease.

ACKNOWLEDGEMENTS

We thank Mr. Edward Carter for his contributions to the research proposal at the initial phase of this project. Authors have no conflict of interest regarding the content of this paper.

REFERENCES

1. Hedreen JC, Roos RAC., Trinucleotide Repeat Disorders, Huntington's Disease, chapter 5 in Dickson DW (ed.), Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders, ISN Neuropath Press, Basel, pp 229-241, 2003.
2. Roos RA. Huntington’s disease: a clinical review. Orphanet J Rare Dis, 2010; 20:5-40. doi: 10.1186/1750-1172-5-40
3. Iuvone T, Esposito G, Filippis DD, Scuderi C, Steardo L. Cannabidiol: A Promising Drug for Neurodegenerative Disorders? CNS Neurosci Ther, 2009; 15(1): 65-75. doi: 10.1111/j.1755-5949.2008.00065.x
4. Kluger B, Triolo P, Jones W, Jankovic J. The therapeutic potential of cannabinoids for movement disorders. Mov Disord, 2015; 30(3), 313-327. doi: 10.1002/mds.26142
5. Koppel BS, Brust JC, Fife T, Bronstein J, Youssouf S, Gronseth G, Gloss D. Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014; 82(17): 1556-1563. doi: 10.1212/WNL.0000000000003636
6. Savage SR, Romero-Sandoval A, Schatman M, Wallace M, Fancullo G, Mccarberg B, Ware M. Cannabin in Pain Treatment: Clinical and Research Considerations. J Pain, 2016; 17(6):654-668. doi: 10.1016/j.jpain.2016.02.007
7. Fernández-Ruiz J, Sagredo O, Pazos MR, García C, Pertwee R, Mechoulam R, Martinez-Orgado J. Cannabinoidol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol. 2013; 75(2):323-333. doi: 10.1111/j.1365-2125.2012.04341.x.

8. ProCon.org. Legal Medical Marijuana States and DC; Laws, Fees, and Possession Limits. July 2019; Available from https://medicalmarijuana.procon.org/legal-medical-marijuana-states-and-dc/.

9. National Institute of Neurological Disorders and Stroke (NINDS). Huntington’s Disease: Hope Through Research. NIH. 2020. Available from https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Hope-Through-Research/Huntingtons-Disease-Hope-Through.

10. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicenter randomised placebo-controlled trial. Lancet. 2003; 362(9395): 1517-1526. doi:10.1016/s0140-6736(03)14738-1.

11. Vaney C, Heinzl-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U., . . . Reif, M. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler, 2004; 10(4):417-424. doi:10.1191/1352458504ms1048oa.

12. Brady CM, Dasgupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler, 2004; 10(4):425-433. doi:10.1191/1352458504ms1063oa.

13. Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O., . . . Davies P. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols® (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol, 2011; 18(9):1122-1131. doi:10.1111/j.1468-1331.2010.03328.x.

14. Venderová K, Růžička E, Voříšek V, Višňovský P. Survey on cannabis use in Parkinson’s disease: Subjective improvement of motor symptoms. Mov Disord, 2004; 19(9): 1102-1106. doi:10.1002/mds.20111.

15. Lotan I, Treves TA, Roditi Y, Djalalotti R. Cannabis (Medical Marijuana) Treatment for Motor and Non-Motor Symptoms of Parkinson Disease. Clin Neuropharmacol, 2014; 37(2): 41-44. doi:10.1097/wnpf.0000000000000016.

16. Fiz J, Durán M, Capellá D, Carbonell J, Farré M. Cannabis Use in Patients with Fibromyalgia: Effect on Symptoms Relief and Health-Related Quality of Life. PLoS ONE, 2011; 6(4): doi:10.1371/journal.pone.0018440.

17. Tringale R, Jensen C. Cannabis and insomnia. O'Shaughnessy’s, The Journal of Cannabis in Clinical Practice, 2011 (Autumn); 31-32. Available from http://files7.webydo.com/92/92209805/UploadedFiles/5E9EC245-448E-17B2-C7CA-21C6BDC6852D.pdf.

18. Cameron C, Watson D, Robinson J. Use of a Synthetic Cannabinoid in a Correctional Population for Posttraumatic Stress Disorder-Related Insomnia and Nightmares, Chronic Pain, Harm Reduction, and Other Indications. J Clin Psychopharmacol, 2014; 34(5):559-564. doi:10.1097/jcp.0000000000000180.

19. Curtis A, Rickards H. Nabilone Could Treat Chorea and Irritability in Huntington’s Disease. J Neuropsychiatry Clin Neurosci, 2006; 18(4):553-554. doi:10.1176/appi.neuropsych.18.4.553.

20. Curtis A, Mitchell I, Patel S, Ives N, Rickards H. A pilot study using nabilone for symptomatic treatment in Huntington’s disease. Mov Disord, 2009; 24(15):2254-2259. doi:10.1002/mds.22809.

21. Saft C, Von Hein SM, Lücke T, Thiels C, Peball M, Djamshidian A., . . . Seppi K. Cannabinoids for Treatment of Dystonia in Huntington’s Disease. J Huntington Dis, 2018; 7(2):167-173. doi:10.3233/JHD-170283.

22. López-Sendón Moreno JL, García Caldentey J, Trigo Cubillo P, Ruiz Romero C, García Ribas G, Alonso Arias MAA, … García de Yébenes Prous J. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex® in Huntington’s disease. J Neurol, 2016; 263(7): 1390–1400. doi:10.1007/s00415-016-8145-9.

23. Blázquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E., . . . Guzmán M. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease. Brain, 2010; 134(1):119-136. doi:10.1093/brain/awq278.

24. Valdeoliva S, Sagredo O, Delgado M, Pozo M. Fernández-Ruiz, J. Effects of a Sativex®-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington’s Disease. Int J Mol Sci, 2017; 18(4):E684. doi:10.3390/ijms18040684.

25. Wissel J, Haydn T, Müller J, Brenneis C, Berger T, Poewe W, Schelsky LD. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain. J Neurol, 2006; 253:1337–1341. doi:10.1007/s00415-006-021-8.

26. Yanes JA, McKinnell ZE, Reid MA, Busler JN, Michel JS, Pangelinan MM, … Robinson JL. Effects of cannabinoid administration for pain: A meta-analysis and meta-regression. Exp Clin Pharmacol. 2019; 27(4):370–382. doi:10.1037/pho0000281.